Registration 333-292283
- Gross proceeds
- 317700000.0
- Net proceeds
- 295461000.0
- Deal price
- 18.0
- Shares
- 17650000
- Offering price
- $18.00
- Ticker
- AKTS
Underwriters: J.P. Morgan, BofA Securities, Leerink Partners, TD Cowen
Company research
Aktis Oncology, Inc.
CIK 2035832Updated Nov 14, 2026
SecurityAKTS · NASDAQ · equity
Historical securities (1)
AKTS · NASDAQ · equity · closed Oct 22, 2026AKTS price & chart
Loading TradingView…
NASDAQ:AKTS on TradingView ↗About the company
We are a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The field of targeted radiopharmaceuticals is currently led by two marketed products that illustrated transformative survival outcomes and quality of life benefits can be conferred by delivering radioisotopes to solid tumors. These leading products, which target prostate specific membrane antigen or somatostatin-2 receptor, are each currently approved in only one tumor type yet have seen considerable commercial uptake and have become fundamental pillars of cancer treatment. Despite these advances, we believe that the field of radiopharmaceuticals is still in its infancy, with many emerging companies still primarily focused on these same two targets. In contrast, we see a significant opportunity to broaden the cancer patient populations benefiting from targeted radiopharmaceuticals by developing next-generation technologies that expand the scope of tumor targets for which it is possible to safely deliver a powerful payload of an alpha-emitting radioisotope. To ensure pa…
In the news
No coverage from other publishers is available.
Recent filings
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
144 filing
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Offerings
Filing attachments
ck0002035832-ex99_1.htm · 8-K · 2026-11-12
Aktis Oncology Reports Third-Quarter Financial Results and Highlights Clinical Trial Progress • Initiated the Company’s third Phase 1b clinical trial, BActinium-2, broadening the evaluation of AKY-2519 to lung cancer and other B7-H3 expressing tumors • Started first backfill cohorts in the ongoing Phase 1b NECTINIUM-2 clinical trial of AKY-1189 and Phase 1b BActinium-1 clinical trial of AKY-2519 • On track to present preliminary data for AKY-1189 in first quarter of 2027 and AKY-2519 in 2027 …
Read attachment ↗ck0002035832-ex99_1.htm · 8-K · 2026-08-13
EX-99.1 2 ck0002035832-ex99_1.htm EX-99.1 EX-99.1 Aktis Oncology Reports Financial Results and Business Highlights for the Second Quarter 2026 • Presented first-in-human clinical imaging and dosimetry data for AKY-2519, supporting a broad clinical development program in patients with prostate, lung, and other B7-H3 expressing solid tumors • Enrolling patients in Phase 1b trial of AKY-1189 in locally advanced or metastatic urothelial cancer (mUC) and other Nectin-4 expressing solid tumors …
Read attachment ↗ck0002035832-ex99_1.htm · 8-K · 2026-05-11
EX-99.1 2 ck0002035832-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Aktis Oncology Reports Financial Results and Business Highlights For First Quarter 2026 • Announced two-trial clinical development strategy for AKY-2519 enabling evaluation in multiple patient segments • Initiated Phase 1b clinical trial of AKY-2519 in metastatic castration-resistant prostate cancer (mCRPC); expect preliminary data in 2027 • Announced AKY-2519 clinical imaging and dosimetry data presentation at upcoming 2026…
Read attachment ↗d110479dex991.htm · 8-K · 2026-04-16
EX-99.1 2 d110479dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Aktis Oncology Appoints Industry Research and Development Veteran Glenn Gormley, MD, PhD to its Board of Directors BOSTON - April 16, 2026 - Aktis Oncology, Inc. (NASDAQ:AKTS) (the “Company”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large populations, including those not addressed by existing platform technologies, today announced the appointment of Glenn …
Read attachment ↗ck0002035832-ex99_1.htm · 8-K · 2026-03-31
EX-99.1 2 ck0002035832-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Aktis Oncology Announces FDA Clearance of Investigational New Drug Applications for AKY-2519 and Provides Business Updates and Full Year 2025 Financial Results • Progressing vision to expand the reach of targeted radiopharmaceuticals to large patient populations • Anticipating multiple milestones in the next 12 months, including initiation of Phase 1b clinical trial of AKY-2519 in mid-2026 BOSTON, March 30, 2026 (GLOBE NEWSW…
Read attachment ↗ck0002035832-ex4_3.htm · 10-K · 2026-03-30
Exhibit 4.3 Description of Securities of Aktis Oncology, Inc. The following is a summary of the capital stock of Aktis Oncology, Inc. (“Aktis,” the “Company,” “our,” “we” or “us”) and certain provisions of our amended and restated certificate of incorporation (the “Restated Charter”), and our amended and restated bylaws (the “Restated Bylaws”), and certain provisions of Delaware law. This summary does not purport to be complete and is qualified by reference to our Restated Charter and Restated…
Read attachment ↗